NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CHLOR-TRIMETON (chlorpheniramine maleate; pseudoephedrine sulfate) by Bayer. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose and 1 more indications. First approved in 1981.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOR-TRIMETON is an oral extended-release antihistamine/decongestant combination containing chlorpheniramine maleate and pseudoephedrine sulfate. It treats upper respiratory allergy symptoms including rhinitis, nasal congestion, itching, sneezing, and watery eyes associated with hay fever and allergic conditions. The chlorpheniramine blocks H1 receptors to reduce histamine-mediated symptoms, while pseudoephedrine acts as a sympathomimetic to relieve nasal congestion.
LOE Approaching
Mature product nearing loss of exclusivity with declining market position; brand teams should expect reduced headcount and focus on generic transition or niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHLOR-TRIMETON at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.